Cargando…

Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials

Background: Diabetic kidney disease (DKD) is a chronic progressive disorder which is a leading cause of chronic kidney disease (CKD). As an important pathogenesis of DKD, the overproduction of reactive oxygen species (ROS) and the inflammatory response have been considered central mediators in the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Shunlian, Zhou, Qian, Gao, Yang, Yang, Yunjiao, Chen, Huizhen, Yuan, Lijun, Li, Zinan, Chen, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404325/
https://www.ncbi.nlm.nih.gov/pubmed/36034830
http://dx.doi.org/10.3389/fphar.2022.929169
_version_ 1784773612877643776
author Fu, Shunlian
Zhou, Qian
Gao, Yang
Yang, Yunjiao
Chen, Huizhen
Yuan, Lijun
Li, Zinan
Chen, Qiu
author_facet Fu, Shunlian
Zhou, Qian
Gao, Yang
Yang, Yunjiao
Chen, Huizhen
Yuan, Lijun
Li, Zinan
Chen, Qiu
author_sort Fu, Shunlian
collection PubMed
description Background: Diabetic kidney disease (DKD) is a chronic progressive disorder which is a leading cause of chronic kidney disease (CKD). As an important pathogenesis of DKD, the overproduction of reactive oxygen species (ROS) and the inflammatory response have been considered central mediators in the progression of DKD. Herbal products are increasingly being applied as antioxidants and anti-inflammatory agents. Of those, the effect of hydroxyl safflower yellow A (HSYA) on oxidative stress and inflammatory reactions has gradually been investigated for DKD treatment, which may provide therapies for DKD with new insights and promote its application in clinical practice. Methods: We searched CNKI, the Chinese Biomedical Literature Database, the Wanfang Database, PubMed, and Embase from the establishment date of the database to 22 April 2022. The included literature in our study was randomized controlled trials (RCTs) using HSYA to treat DKD. We performed a meta-analysis by calculating the standard mean difference (SMD) with a 95% confidence interval (CI). The inverse-variance method with a random effect was used in our meta-analysis using Stata software and RevMan software. Results: A total of 31 articles with 31 groups containing a total of 2487 participants were included in this meta-analysis. The pooled results showed a statistical improvement in the following measurements: fasting blood glucose (FBG), postprandial blood glucose (PBG), blood urea nitrogen (BUN), urinary albumin excretion rates (UAER), serum creatinine (SCR), hypersensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), fasting insulin (FINS), total cholesterol (TC), triglycerides (TGs), hemoglobin A1c (HbA1C), homeostasis model assessment insulin resistance (HOMA-IR), and malondialdehyde (MDA). Conclusion: HSYA can effectively treat DKD by inhibiting inflammatory reactions and oxidative stress, decreasing blood glucose and blood lipids, and improving renal function indices. However, more RCTs are still needed in the future to further demonstrate the effect of HSYA on biomarkers of oxidative stress and inflammatory reactions in patients with DKD due to the low quality and small sample size of the literature included in this study. Systematic Review Registration: PROSPERO: CRD 42021235689
format Online
Article
Text
id pubmed-9404325
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94043252022-08-26 Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials Fu, Shunlian Zhou, Qian Gao, Yang Yang, Yunjiao Chen, Huizhen Yuan, Lijun Li, Zinan Chen, Qiu Front Pharmacol Pharmacology Background: Diabetic kidney disease (DKD) is a chronic progressive disorder which is a leading cause of chronic kidney disease (CKD). As an important pathogenesis of DKD, the overproduction of reactive oxygen species (ROS) and the inflammatory response have been considered central mediators in the progression of DKD. Herbal products are increasingly being applied as antioxidants and anti-inflammatory agents. Of those, the effect of hydroxyl safflower yellow A (HSYA) on oxidative stress and inflammatory reactions has gradually been investigated for DKD treatment, which may provide therapies for DKD with new insights and promote its application in clinical practice. Methods: We searched CNKI, the Chinese Biomedical Literature Database, the Wanfang Database, PubMed, and Embase from the establishment date of the database to 22 April 2022. The included literature in our study was randomized controlled trials (RCTs) using HSYA to treat DKD. We performed a meta-analysis by calculating the standard mean difference (SMD) with a 95% confidence interval (CI). The inverse-variance method with a random effect was used in our meta-analysis using Stata software and RevMan software. Results: A total of 31 articles with 31 groups containing a total of 2487 participants were included in this meta-analysis. The pooled results showed a statistical improvement in the following measurements: fasting blood glucose (FBG), postprandial blood glucose (PBG), blood urea nitrogen (BUN), urinary albumin excretion rates (UAER), serum creatinine (SCR), hypersensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), fasting insulin (FINS), total cholesterol (TC), triglycerides (TGs), hemoglobin A1c (HbA1C), homeostasis model assessment insulin resistance (HOMA-IR), and malondialdehyde (MDA). Conclusion: HSYA can effectively treat DKD by inhibiting inflammatory reactions and oxidative stress, decreasing blood glucose and blood lipids, and improving renal function indices. However, more RCTs are still needed in the future to further demonstrate the effect of HSYA on biomarkers of oxidative stress and inflammatory reactions in patients with DKD due to the low quality and small sample size of the literature included in this study. Systematic Review Registration: PROSPERO: CRD 42021235689 Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9404325/ /pubmed/36034830 http://dx.doi.org/10.3389/fphar.2022.929169 Text en Copyright © 2022 Fu, Zhou, Gao, Yang, Chen, Yuan, Li and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Fu, Shunlian
Zhou, Qian
Gao, Yang
Yang, Yunjiao
Chen, Huizhen
Yuan, Lijun
Li, Zinan
Chen, Qiu
Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials
title Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials
title_full Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials
title_fullStr Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials
title_short Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials
title_sort antioxidant and anti-inflammatory properties of hydroxyl safflower yellow a in diabetic nephropathy: a meta-analysis of randomized controlled trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404325/
https://www.ncbi.nlm.nih.gov/pubmed/36034830
http://dx.doi.org/10.3389/fphar.2022.929169
work_keys_str_mv AT fushunlian antioxidantandantiinflammatorypropertiesofhydroxylsaffloweryellowaindiabeticnephropathyametaanalysisofrandomizedcontrolledtrials
AT zhouqian antioxidantandantiinflammatorypropertiesofhydroxylsaffloweryellowaindiabeticnephropathyametaanalysisofrandomizedcontrolledtrials
AT gaoyang antioxidantandantiinflammatorypropertiesofhydroxylsaffloweryellowaindiabeticnephropathyametaanalysisofrandomizedcontrolledtrials
AT yangyunjiao antioxidantandantiinflammatorypropertiesofhydroxylsaffloweryellowaindiabeticnephropathyametaanalysisofrandomizedcontrolledtrials
AT chenhuizhen antioxidantandantiinflammatorypropertiesofhydroxylsaffloweryellowaindiabeticnephropathyametaanalysisofrandomizedcontrolledtrials
AT yuanlijun antioxidantandantiinflammatorypropertiesofhydroxylsaffloweryellowaindiabeticnephropathyametaanalysisofrandomizedcontrolledtrials
AT lizinan antioxidantandantiinflammatorypropertiesofhydroxylsaffloweryellowaindiabeticnephropathyametaanalysisofrandomizedcontrolledtrials
AT chenqiu antioxidantandantiinflammatorypropertiesofhydroxylsaffloweryellowaindiabeticnephropathyametaanalysisofrandomizedcontrolledtrials